A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Description

The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.

Conditions

Cancer, Immunotherapy, PD-1, PD-L1, Immune Checkpoint Therapy

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Condition
Cancer
Intervention / Treatment

-

Contacts and Locations

Norwich

Eastern Connecticut Hematology and Oncology, Norwich, Connecticut, United States, 06360

Rock Hill

Carolina Blood and Cancer Care Associates, Rock Hill, South Carolina, United States, 29732

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. 18 years of age or older
  • 2. Stage III or IV cancer
  • 3. Selected by their healthcare provider to receive the Episwitch CiRT® test according to the current evidence-based schedule (per protocol) as part of their standard of practice.
  • 4. ECOG performance status ≤ 2
  • 5. Clinically eligible for ICI therapy
  • 6. Able to read, understand and provide written informed consent.
  • 7. Willing and able to comply with the study requirements
  • 1. Pregnant or breastfeeding
  • 2. History of bone marrow or organ transplant
  • 3. Contra indication for receiving Immune Check Point inhibitor.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Oxford Biodynamics Inc.,

Ryan Mathis, MD, STUDY_DIRECTOR, Oxford BioDynamics

Study Record Dates

2027-05-14